Press Release

Induced Pluripotent Stem Cells Market Analysis by Key Players, Geography and Major Segments Forecast 2018-2026

Induced Pluripotent Stem Cells Market Size, Share, Key Players Overview and Geographical Outlook 2026

The rising shift towards regenerative medicines is driving the global induced pluripotent stem cells, says Fortune Business Insights in a report, titled “Induced Pluripotent Stem Cells Market Size, Share and Global Trend By Derived Cell Type (Amniotic cells, Fibroblasts, Keratinocytes, Hepatocytes, Others), By Application (Regenerative medicines, Drug development, Toxicity testing, Reprogramming technology, Academic research, Others), By End-user (Hospitals, Education & research institutes, Biotechnological companies) and Geography Forecast till 2026.” Active government support through research grants is a factor backing the growth of the global induced pluripotent stem cells.

Get Sample PDF:

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/induced-pluripotent-stem-cells-market-101021

Top Leaders Overview:

Some of the leading companies in the Induced Pluripotent Stem Cells market

  • Astellas Pharma
  • Ncardia
  • Applied StemCell
  • FUJIFILM Cellular Dynamics
  • Axol Bioscience
  • Bristol-Myers Squibb Company
  • R&D Systems
  • Fate Therapeutics
  • Evotec AG
  • ViaCyte Inc

Launch of mTeSR™ Plus by STEMCELL Technologies Will Augment Growth

STEMCELL Technologies Inc., a global biotechnology company launched mTeSR™ Plus, an enhanced version of mTeSR™1, a widely published feeder-free human pluripotent stem cell (hPSC) maintenance medium. mTeSR™ Plus will be used to prevent onset acidosis. The launch of mTeSR™ Plus is likely to encourage global induced pluripotent stem cells growth owing to the design of the mTeSR™ Plus, which offers more consistent cell culture environment through sustained medium pH and stabilized components including FGF2.

Furthermore, warning by FDA for marketing dangerous unapproved stem cells products is expected to alert pharmaceutical companies to market FDA approved products. This factor will, in turn, enable growth of the global induced pluripotent stem cells. For instance, the U.S Food and Drug Administration (FDA) sent a warning to Genetech, Inc. for marketing stem cell therapy without the U.S FDA approval and nonconformity of Good Manufacturing Practice (CGMP).

Browse Complete Report:

https://www.fortunebusinessinsights.com/industry-reports/induced-pluripotent-stem-cells-market-101021

Major Segmental Overview:

  • By Derived Cell Type
  • By Application
  • By End-user
  • By Geography

Rising Shift Towards Regenerative Medicines Will Facilitate Growth

Active government support for R&D activities through research grants is driving the global induced pluripotent stem cells. Increasing private funding and rising shift towards regenerative medicines are predicted to favor induced pluripotent stem cells revenue. Further, induced pluripotent stem cells have created new avenues in clinical research, regenerative medicines, and disease modeling.

This has also paved the way to numerous mergers and acquisitions and potential pipeline products and patents. In addition, the diversity of donor candidates is a factor predicted to aid induced pluripotent stem cells growth. Moreover, increasing accessibility towards the cell of origin is also expected to boost the global induced pluripotent stem cells market in the forthcoming year. However, ethical issues related to the donors and potential risk of tumors are factors predicted to hamper the growth of the global induced pluripotent stem cells.

Rising R&D Investment by Key Players Will Accelerate Growth in North America

Geographically, the global market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global induced pluripotent stem cells market during the forecast period due to the increasing R&D investment by key players for potential pipeline products. In Europe, the global induced pluripotent stem cells market is anticipated to grow significantly during the forecast period.

The active government support and product launches are predicted to favor growth in the region. For instance, in 2018, Ncardia, a company working for drug discovery using stem cell, launched Xpress.4U LightPace Cor.4U, a kit for improving and simplifying the use of optical pacing of cardiomyocytes, a human induced pluripotent stem cell. The aforementioned factors together are enabling growth in Europe.

Some of the major companies that are present in the global market are Astellas Pharma Inc., Ncardia, Applied StemCell, FUJIFILM Cellular Dynamics Inc., Axol Bioscience Ltd., Bristol-Myers Squibb Company, R&D Systems Inc., Fate Therapeutics, Evotec AG, ViaCyte Inc., and other players.

STRONG INDUSTRY FOCUS:

  • Extensive product offerings
  • Customer research services
  • Robust research methodology
  • Comprehensive reports
  • Latest technological developments
  • Value chain analysis
  • Potential market oppertunities
  • Growth dynamics
  • Quality assurance
  • Post-sales support
  • Regular report updates

Speak to Analyst:

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/induced-pluripotent-stem-cells-market-101021

View Related Reports:

Food Cultures Market Size, Share and Geography Forecast till 2026

Refrigerated Transport Market 2019: Global Size, Growth Factors, Top Leaders, Opportunities, Emerging Technologies and Regional Forecast to 2026

Animal Care Services Market 2019 Global Trends, Size, Share, Industry Growth by Forecast to 2026

Tags

Jesus Rust

Jesus is leading the environment column. He is a very renowned environmentalist and has worked in many projects, some of which are based in faraway lands too. He always encourages environment conservation and sometimes keeps small group talks about the concerns. His writing and editing skills act the cheery on the top of the cake.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close